Topic: Brain tumor cell invasion and metastasis: anatomical, biological and clinical considerations

Download All Articles

A special issue of Journal of Cancer Metastasis and Treatment  (Print ISSN:2394-4722; Online ISSN:2454-2857).

Deadline for manuscript submissions: 18 May 2016

Share This Special Issue

Guest Editor(s)

  • Michael A. Grotzer, MD, PhD
    Department of Oncology, University Children's Hospital of Zurich, Steinwiesstrasse 75, Zurich 8032, Switzerland.

    Website | E-mail

Special Issue Introduction:

As cancer is a global epidemic which knows no borders, efforts to better understand biology and to control it should know no borders either. This issue contains a mixture of clinical and preclinical scholarly articles that have been written by scientists from America, Europe, and the Middle East. I hope that the fresh insights represented here will be appreciated by neuro-oncologists and brain cancer researchers across the translational spectrum.

Keywords:

Brain tumor cell invasion, brain tumor cell metastasis, PI3K/AKT/mTOR pathway, brain cancer biomarkers

Submission Information:

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://jcmtjournal.com/pages/view/author_instructions
For Online Submission, please login at https://mc03.manuscriptcentral.com/jcmt
Submission Deadline: 18 May 2016
Contacts: Dandan Yu, Managing Editor, dandanyu@oaepublish.com

Published Articles Download All Articles
  • Targeting cerebrospinal fluid for discovery of brain cancer biomarkers

    Tarek Shalaby , Federica Achini , Michael A. Grotzer
    Central nervous system (CNS) cancer is a devastating illness with unmet therapeutic needs. Establishing biomarkers that have the potential to guide accurate CNS cancer diagnosis or are helpful in predicting disease progression or therapy response is of great interest. Cerebrospinal fluid (CSF) has been extensively targeted for the detection of molecules that might be useful markers for cancer detection. However, so far very few of such markers have found a standardized routine clinical application. This review examines the current scientific knowledge about the biochemical elements in the... Read more
    J Cancer Metastasis Treat 2016;2:176-87. | doi:10.20517/2394-4722.2016.12
    Published on: 18 May 2016  | Viewed:30996  | Downloaded:590
    +HTML| PDF
  • Gemcitabine followed by radiotherapy in treatment of newly diagnosed high-grade gliomas

    Maha El-Naggar , Mervat Omar , Ahmed Elgeriany , Godefridus J. Peters , Amina Mostafa , Samir Shehata
    Aim: High-grade glioblastoma multiforme (GBM) has a poor median overall survival (OS). The standard treatment after surgery is temozolomide and radiotherapy (RTH). Patients with unmethylated methylguanine-methyltransferase promoter (MGMT) have no or little benefit from temozolomide and are eligible for alternative therapies. Gemcitabine is a good radiosensitizer. We aimed to evaluate the combination of gemcitabine with RTH in newly diagnosed GBM. Methods: The study was a prospective phase II study. Eligible patients were required to have histologically proven anaplastic astrocytoma or GBM.... Read more
    J Cancer Metastasis Treat 2016;2:188-94. | doi:10.20517/2394-4722.2016.15
    Published on: 18 May 2016  | Viewed:3318  | Downloaded:251
    +HTML| PDF
  • Introduction to this special issue on brain tumor cell invasion and metastasis: anatomical, biological and clinical considerations

    Michael A. Grotzer
    It is my privilege to introduce the readers to this special issue entitled “Brain tumor cell invasion and metastasis: anatomical, biological and clinical considerations”. As cancer is a global epidemic which knows no borders, efforts to better understand biology and to control it should know no borders either. This issue contains a mixture of clinical and preclinical scholarly articles that have been written by scientists from America, Europe, and the Middle East. I hope that the fresh insights represented here will be appreciated by neuro-oncologists and brain cancer researchers across the... Read more
    J Cancer Metastasis Treat 2016;2:147-8. | doi:10.20517/2394-4722.2016.23
    Published on: 18 May 2016  | Viewed:657  | Downloaded:115
    +HTML| PDF
  • Dissecting brain tumor growth and metastasis in vitro and ex vivo

    Michael A. Grotzer , Anuja Neve , Martin Baumgartner
    Local infiltration and distal dissemination of tumor cells hamper efficacy of current treatments against central nervous system (CNS) tumors and greatly influence mortality and therapy-induced long-term morbidity in survivors. A number of in vitro and ex vivo assay systems have been established to better understand the infiltration and metastatic processes, to search for molecules that specifically block tumor cell infiltration and metastatic dissemination and to pre-clinically evaluate their efficaciousness. These systems allow analytical testing of tumor cell viability and motile and... Read more
    J Cancer Metastasis Treat 2016;2:149-62. | doi:10.20517/2394-4722.2016.02
    Published on: 18 May 2016  | Viewed:17109  | Downloaded:634
    +HTML| PDF
  • Interdisciplinary management of central nervous system metastasis and neoplastic meningitis: recent developments and future perspectives

    Ghazaleh Tabatabai , Marilin Koch , Cristiana Roggia , Juliane Ebert , Claus Garbe , Friedegund Meier , Sara Brucker , Eva Maria Grischke , Diethelm Wallwiener , Robert Möhle , Lothar Kanz , Walter Erich Auletzky , Ulrike Ernemann , Christian LaFougere , Konstantin Nikolaou , Bernd Pichler , Jens Schittenhelm , Manuela Neumann , Falko Fend , Stefan Czemmel , Sven Nahnsen , Frank Paulsen , Daniel Zips , Maike van Lessen , Hans-Otto Karnath , Ulf Ziemann , Hans-Georg Rammensee , Constantin Roder , Marco Skardelly , Jürgen Bernd Honegger , Marcos Tatagiba
    The incidence of metastatic disease in the central nervous system (CNS) is rising. According to current estimates, up to a third of adult cancer patients will suffer from CNS metastasis. Clinical evidence-based data from prospective randomized trials are rare, however, because CNS metastasis patients were often excluded from clinical trial participation. The management of CNS metastasis patients is therefore rather ill-defined and an interdisciplinary challenge. Recent basic and translational science data have begun contributing to a more profound understanding of the molecular mechanisms... Read more
    J Cancer Metastasis Treat 2016;2:163-75. | doi:10.20517/2394-4722.2016.01
    Published on: 18 May 2016  | Viewed:2863  | Downloaded:157
    +HTML| PDF
  • Brain tumor surgery: supplemental intra-operative imaging techniques and future challenges

    Telmo Augusto Barba Belsuzarri , Raphael Martinelli Anson Sangenis , João Flavio Mattos Araujo
    Modern brain tumor surgery stands in the pillar of maximum safe resection. Tumor borders are always challenging, especially infiltration zones in malignant brain tumors. Novel technologies are designed for a better delineation and to increase the extent of resection (EOR) in brain tumor surgery, such as: cortical and sub-cortical mapping strategies with somatosensory-evoked potentials, awake stimulation mapping and cortical/sub-cortical stimulation for motor pathways, important for resection in eloquent areas; intra-operative imaging as functional and intra-operative magnetic resonance... Read more
    J Cancer Metastasis Treat 2016;2:70-9. | doi:10.4103/2394-4722.172249
    Published on: 11 Mar 2016  | Viewed:4861  | Downloaded:287
    +HTML| PDF
  • The role of the PI3K/AKT/mTOR pathway in brain tumor metastasis

    Silvia Crespo , Marcus Kind , Alexandre Arcaro
    The PI3K/AKT/mTOR (PAM) pathway is involved in a variety of cellular functions and often contributes to oncogenesis and cancer progression. It has been recognized that this pathway is frequently activated in the most common central nervous system cancers of adults and children, malignant gliomas and medulloblastomas (MB). In these tumors, the PAM network controls key functions necessary for cell invasion and metastasis, such as cell motility. This review summarizes the current knowledge about the role of PAM signaling in cell invasion and metastasis in gliomas and MB. Current approaches to... Read more
    J Cancer Metastasis Treat 2016;2:80-9. | doi:10.20517/2394-4722.2015.72
    Published on: 11 Mar 2016  | Viewed:27568  | Downloaded:760
    +HTML| PDF
  • Brain infiltration by cancer cells: different roads to the same target?

    Mayra Paolillo , Sergio Schinelli
    Brain infiltration by cancer cells is a complex process in which metastatic cells detached from the primary tumor must firstly survive in the blood flow, cross the blood brain barrier (BBB) and finally colonize a foreign microenvironment. The cells that successfully bypass the cellular barriers surrounding capillaries, proliferate to form micrometastasis and trigger the angiogenetic process. Different molecular mechanisms have been proposed to explain the metastatic behaviour of solid tumors that infiltrate brain tissue; in this review the most recent findings concerning mechanisms and genes... Read more
    J Cancer Metastasis Treat 2016;2:90-100. | doi:10.4103/2394-4722.172661
    Published on: 11 Mar 2016  | Viewed:2291  | Downloaded:248
    +HTML| PDF
  • Effects of Gas1 on gliomas: a review on current preclinical studies

    Jose Segovia , Elizabeth Bautista , Manuel Lara-Lozano
    Glioblastoma multiforme (GBM) is the most common and lethal brain tumor. Its prognosis remains very poor, despite the use of combined treatments such as surgical resection, radiation and chemotherapy. The major limitations for the treatment of GBM are its high invasiveness, tumor recurrence and resistance to treatments. Therefore, gene therapy appears as a relevant strategy for its treatment. Thus, we have investigated the use of growth-arrest-specific 1 (Gas1) for the treatment of GBM. Gas1 is a tumor suppressor protein that inhibits glioma growth by inducing arrest and apoptosis of tumor... Read more
    J Cancer Metastasis Treat 2016;2:101-11. | doi:10.20517/2394-4722.2015.76
    Published on: 11 Mar 2016  | Viewed:4766  | Downloaded:234
    +HTML| PDF
  • Tailored nanocarriers and bioconjugates for combating glioblastoma and other brain tumors

    Fatema ELAmrawy , Amr A. Othman , Chris Adkins , Aliaa Helmy , Mohamed I. Nounou
    Worldwide, the incidence of primary brain tumors is on the rise. Unfortunately, noninvasive drug therapy is hampered by poor access of most drugs to the brain due to the insurmountable blood-brain barrier (BBB). Nanotechnology holds great promise for noninvasive therapy of severe brain diseases. Furthermore, recent bioconjugation strategies have enabled the invasion of the BBB via tailored-designed bioconjugates either with targeting moieties or alterations in the physicochemical and/or the pharmacokinetic parameters of central nervous system (CNS) active pharmaceutical ingredients.... Read more
    J Cancer Metastasis Treat 2016;2:112-22. | doi:10.20517/2394-4722.2015.78
    Published on: 11 Mar 2016  | Viewed:29720  | Downloaded:850
    +HTML| PDF
Journal of Cancer Metastasis and Treatment ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.